Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387033 · ClinicalTrials.gov registry record · NA
Role of Virtual Reality (VR) in Patients With Sickle Cell Disease (SCD)
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT03387033 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 20 participants.
The verdict
NCT03387033, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Patients with sickle cell disease (SCD) and cancer often have complicated courses while hospitalized and often deal with pain, anxiety and depression. Advances in the field of technology provide potential avenues for innovative and improved care models for our patients. Virtual reality (VR) has been recently utilized to improve anxiety and pain in a variety of patient populations including children undergoing elective surgery and children experiencing intravenous cannulation in the Emergency Department. Patients with SCD and cancer, both adults and children, are a group of patients that can benefit from VR as part of their care. Over the past four years, our team has successfully implemented several self-developed mobile applications ("apps") for our patients, in addition to integrating objective data (heart rate, activity, stress) from wearable activity trackers. The investigators now propose implementing a feasibility study followed by a pilot study and randomized-controlled trial of the use of VR in patients with SCD and cancer. The investigators plan to assess pain and anxiety prior to the session as well as following the session in hospitalized patients and outpatients with SCD and cancer. The sessions will include a ten-minute relaxation response introductory narrative segment (deep breathing and mindfulness) followed by a ten-minute narrated and immersive VR. Heart rate will be tracked using an Apple iWatch for 30 minutes prior to the session, during the session, and following the session. We anticipate VR will not only be a feasible method to provide non-pharmacologic treatment, but will also significantly reduce pain and anxiety.
Interventions
- DEVICE Relaxation response and virtual reality (VR) session
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-02-05 |
| Est. Completion | 2019-04-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03387033
The ClinicalTrials.gov registry entry for NCT03387033 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Relaxation response and virtual reality (VR) session is the first listed.
NCT03387033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03387033 about?
NCT03387033 is a clinical study titled "Role of Virtual Reality (VR) in Patients With Sickle Cell Disease (SCD)". Patients with sickle cell disease (SCD) and cancer often have complicated courses while hospitalized and often deal with pain, anxiety and depression. Advances in the field of technology provide potential avenues for innovative and improved care models for our patients. Virtual reality (VR) has been...
What is the current status of trial NCT03387033?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2018-02-05. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT03387033?
The interventions under investigation include: Relaxation response and virtual reality (VR) session (DEVICE).
Who is sponsoring clinical trial NCT03387033?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.